Brief: Adamis Pharmaceuticals Provides Update On Clinical Study Assessing Tempol For The Treatment Of COVID-19
14/03/2022 12:22
March 14 (Reuters) - Adamis Pharmaceuticals Corp ADMP.O :
* ADAMIS PHARMACEUTICALS PROVIDES UPDATE ON CLINICAL STUDY
ASSESSING TEMPOL FOR THE TREATMENT OF COVID-19
* ADAMIS PHARMACEUTICALS CORP - DSMB RECOMMENDED THAT STUDY
CONTINUE WITHOUT MODIFICATION
Source text for Eikon: ID:nGNX3089dX
Further company coverage: ADMP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on DMK Pharmaceuticals
See all newsBrief: Dmk Pharmaceuticals Corp Says Ebrahim Versi Resigned As Chairman
Brief: ZMI Pharma Finalized Acquisition Of All Strategic Assets Necessary To Manufacture Zimhi From Dmk Pharma
Brief: DMK Pharmaceuticals Files For Chapter 11 Bankruptcy In The U.S. - Court Filing
Brief: Dmk Pharmaceuticals Regains Full Rights To Commercialize Zimhi
Brief: DMK Pharmaceuticals Regains Full Rights From US Worldmeds For Symjepi And Provides Corporate Update